ArticleJournal of kidney cancer and VHL2026
Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III Renal Cell Carcinoma.
Neil Rakheja et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.